Serum Institute to seek nod for two full-dose regimen of Covishield

Suresh Jadhav, executive director of the Pune-based firm, said on Friday Serum was seeking approval from the Drug Controller General of India (DCGI) for the two-full dose regimen

Coronavirus, vaccine, covid, drugs, clinical trials

Premium

Trials in India over 1,600 people was done with two-full doses and the data has been submitted to the regulator

Mumbai/London

2 min read Last Updated : Dec 19 2020 | 0:26 AM IST

Serum Institute of India will seek approval for a two full-dose regimen from the Indian drug regulator after its partner, Oxford University, cited data from early trials and said following

Topics : Coronavirus Vaccine Serum Institute of India AstraZeneca Oxford University

First Published: Dec 19 2020 | 0:22 AM IST

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Continue

Serum Institute to seek nod for two full-dose regimen of Covishield

Suresh Jadhav, executive director of the Pune-based firm, said on Friday Serum was seeking approval from the Drug Controller General of India (DCGI) for the two-full dose regimen

Also Read

Serum likely to submit final Covid-19 vaccine trial data in 10 days

Path to normalcy via herd immunity

Covid-19: Indian sites await DCGI nod to restart Oxford vaccine trial

What Serum Institute's persistence on Oxford vaccine trials means for India

Serum Institute to start phase-2 trials of Oxford-AstraZeneca vaccine

COVAX gains access to 2 billion doses of vaccines for 190 member economies

SC directs states to form panels for fire audit of Covid hospitals

Covid vaccination voluntary, those already infected can also get the jab

Virus spread like wild fire over ineffective policy implementation: SC

India to produce 300 mn doses of Sputnik V vaccine in 2021: Report

Explore News